# Caffeine for Hypoxic-Ischemic Encephalopathy

> **NCT03913221** · PHASE1 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 17 (actual)

## Conditions studied

- Hypoxic-Ischemic Encephalopathy

## Interventions

- **DRUG:** Caffeine Citrate 5 mg/kg
- **DRUG:** Caffeine Citrate 10 mg/kg

## Key facts

- **NCT ID:** NCT03913221
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-14
- **Primary completion:** 2023-01-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03913221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03913221, "Caffeine for Hypoxic-Ischemic Encephalopathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03913221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*